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Bronchiolitis obliterans (BO) is a late onset complication of allogeneic hematopoi-
etic stem cell transplantation (HSCT), and treatment outcome is dismal if it does 
not respond to immunosuppressive therapy. A 21-year-old male diagnosed with 
acute myeloid leukemia received an allogeneic HSCT from human leukocyte anti-
gen-identical sibling donor. Twenty one months after transplantation, he developed 
progressive dyspnea and was diagnosed BO. Despite standard immunosuppressive 
therapy, the patient rapidly progressed to respiratory failure and Novalung® inter-
ventional lung-assist membrane ventilator was applied in the intensive care unit. 
Three months after the diagnosis of BO, the patient underwent bilateral lung trans-
plantation (LT) and was eventually able to wean from the ventilator and the No-
valung®. Since the LT, the patient has been under a strict rehabilitation program in 
order to overcome a severe lower extremity weakness and muscle atrophy. Histo-
logic findings of the explanted lungs confirmed the diagnosis of BO. Nine months 
after the LT, the patient showed no signs of rejection or infectious complications, 
but still required rehabilitation treatment. This is the first LT performed in a patient 
with BO after allogeneic HSCT in Korea. LT can be an effective therapy in terms 
of survival for patients with respiratory failure secondary to development of BO 
following HSCT. 
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INTRODUCTION
Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative treatment 
for many hematologic malignancies including acute myeloid leukemia (AML).1 
However, chronic graft-versus-host disease (GVHD) is a major complication and 
a main cause of late mortality following allogeneic HSCT.2-4 Bronchiolitis obliter-
ans (BO) is a late onset noninfectious pulmonary complication occurring in 10% 
to 15% of patients with extensive chronic GVHD.3 The mortality rate of BO after 
HSCT is very high, although BO is treated with high-dose systemic corticosteroid 
and immunosuppressive agents as in chronic GVHD. Furthermore, to our best 
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Staphylococcus aureus (methicillin-resistant Staphylococcus 
aureus). Pulmonary function test showed evidence of BO 
with reduction in forced expiratory volume in one second 
(25% of expected) and diffusion capacity (48% of expect-
ed). Despite standard immunosuppressive therapy consist-
ing of steroid, FK-506, and mycophenolate mofetil, the 
symptoms aggravated, and rapidly progressed to respiratory 
failure and became completely dependent on oxygen supply 
via mechanical ventilator. Hypercapnea could not be man-
aged even with mechanical ventilator support, and therefore, 
Novalung® interventional lung-assist membrane was applied. 
There was no other therapeutic option except lung trans-
plantation (LT) in order to treat end-stage BO, therefore, he 
was transferred to our hospital. Three months after the on-
set of BO and one month after the Novalung® application, 
he underwent bilateral LT from unrelated donor. Post-trans-
plant course for LT was uneventful, and the patient was 
able to wean from the Novalung® on postoperative day 
(POD) 1 day and from the ventilator on POD 16 days. His-
tologic examination of the explanted lung showed obliterat-
ed bronchiole, patch interstitial fibrosis and intra-alveolar 
knowledge, there are no controlled trials regarding the 
treatment of BO. The role of immunosuppressive agents is 
marginal in BO and many other therapeutic strategies have 
been reported. There are a few reports of lung transplanta-
tion (LT) in BO with encouraging results,5 and we report a 
first successful case of LT for BO following allogeneic 
HSCT in Korea. 
CASE REPORT
A 21-year-old male diagnosed as AML received an alloge-
neic HSCT from his human leukocyte antigen-identical sib-
ling donor. Twenty one months after the transplantation, the 
patient was admitted due to progressive dyspnea, and com-
puterized tomography examination of the chest showed dif-
fuse bronchiectasis and air-trapping in both lungs with peri-
bronchial ground glass opacity (Fig. 1), which was 
compatible with BO combined with pneumonia. Sputum 
culture showed the growth of pseudomonas aeruginosa, 
while bronchial washing culture showed the growth of 
Fig. 1. Chest computed tomography. Diffuse bronchiectasis and airtrapping in both lungs with peribronchial graund glass opacity more predominantly in 
both upper lobe. It is consistent with underlying bronchiolitis obliterans combined with pneumonia.
Fig. 2. Microscopic findings of the lung. The biopsy showed the obliterated bronchiole and patchy interstitial fibrosis and intraalveolar collection of histio-
cytes (A: H&E stain ×100, B: H&E stain ×200).
A B
Yu Ri Kim, et al.
Yonsei Med J   http://www.eymj.org   Volume 53   Number 5   September 20121056
treated with single LT following HSCT.3,13-15 Recently, Os-
hima, et al.16 reported a living-donor lobar lung transplanta-
tion for therapy-resistant BO after allogenetic HSCT from 
the same donor of bone marrow. In general, the donor of LT 
is different from hematopoietic stem cell donor. Therefore, 
there is high risk of rejection and may develop BO event in 
the transplanted lung. It has been reported that allogeneic 
HSCT would increase the risk of rejection after LT because 
of the amount of immunocompetent leukocytes present in 
the donor lung. However, most of LT do not experience 
graft rejection because long term immunosuppresion prior 
to LT might have induced a down-regulation of alloreactiv-
ity.5,13,17 In our case, the patient did not experience graft re-
jection.  
Herein, we report the first case of LT for BO after alloge-
neic HSCT in Korea. Prior to LT, the patient was complete-
ly dependent on mechanical ventilator and rapidly pro-
gressed to respiratory failure. After LT, the patient underwent 
rehabilitation without any sign of respiratory failure or graft 
rejection, and needed special attention regarding the infec-
tious complications or post transplant lymphoproliferative 
disorders. LT could be an effective therapy in terms of quali-
ty of life and survival for patients with respiratory failure 
secondary to the development of BO after allogeneic HSCT. 
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